CARDIONOVUM GmbH
Massimo Morero serves as the Chief Technology Officer at CARDIONOVUM GmbH since October 2022. Prior experience includes roles as Key Account Manager at Teleflex, Research and Development at AngioBeat, and Sr. Product Development Manager at Medtronic from 2010 to 2021, where responsibilities encompassed identifying business opportunities, guiding technology conceptualization, managing cross-functional teams, and overseeing new concepts development. Massimo Morero also held the position of Product Development Manager at INVATEC, focusing on endovascular devices, and began a career as a Research and Development Engineer at Sorin Biomedica Cardio S.r.l. Massimo Morero holds a Bachelor's degree in Mechanical Engineering from Politecnico di Torino.
This person is not in any offices
CARDIONOVUM GmbH
CARDIONOVUM, a medical technology company based in Bonn, Germany, develops and commercializes innovative medical devices such as the new generation of DCB and drug-eluting stents for the treatment of coronary and peripheral artery disease. The company’s pioneering range of DCBs is based on the SAFEPAX® paclitaxel coating matrix which has the lowest wash-off rates on the market. The company’s strong commitment to clinical research ensures a continually deepening and expanding evidence-base in support of the clinical benefits of our products. Pioneers in medical devices. The worldwide first CE-approved DCB. With the first DCB market introduction, CARDIONOVUM contributed significantly to the establishment of a new medical device therapy to treat coronary and peripheral artery disease effectively. CARDIONOVUM consists of R & D staff, with the longest and most profound experience, in developing clinically advanced DCB and DES cardiovascular devices. “Live Deserves the Best”